X. Sheng & al., «1692P A phase Ib/IIa trial to evaluate the safety and efficacy of PM8002/ BNT327, a bispecific antibody targeting PD-L1 and VEGF-A, as a monotherapy in patients with advanced renal cell carcinoma», Annals of Oncology, vol.35, (lire en ligne).